{"page_content": "SASB Index \nThe following table provides data and information for Apellis utilizing the Sustainable Accounting Standards Board \n(SASB) Biotechnology and Pharmaceuticals standard. The data represents full-year 2021 performance.\nCategories Accounting Metric Code Information\nSafety of Clinical  \nTrial ParticipantsDiscussion, by world region, of management \nprocess for ensuring quality and patient safety \nduring clinical trialsHC-BP-210a.1 We are committed to ensuring the \nsafety, health, and well-being of \nour clinical trials participants and to \nhaving the highest ethical, scientific, \nand clinical standards in all of our \nresearch endeavors. All clinical \ntrials follow Good Clinical Practice \n(GCP) and Good Pharmacovigilance \nPractice (GVP)\nFor details, see the section Quality  \nand Safety\nNumber of FDA Sponsor Inspections related to \nclinical trial management and pharmacovigilance \nthat resulted in: \n(1) Voluntary Action Indicated (VAI) and \n(2) Official Action Indicated (OAI)HC-BP-210a.2 Not reported\nTotal amount of monetary losses as a result of \nlegal proceedings associated with clinical trials \nin developing countriesHC-BP-210a.3 Any material legal or regulatory \nissues would be disclosed in annual \n10-K and quarterly 10-Qs\nAccess to  \nMedicinesDescription of actions and initiatives to promote \naccess to health care products for priority \ndiseases and in priority countries as defined by \nthe Access to Medicine IndexHC-BP-240a.1 Patients are at the forefront of what \nwe do, and we are committed to \nensuring that every eligible patient \nwho wants our medicine will have \naccess regardless of ability to pay\nFor details, see the section Patients \nand Access to Medicine\nList of products on the WHO List of Prequalified \nMedicinal Products as part of its Prequalification \nof Medicines Programme (PQP)HC-BP-240a.2 Given the focus on rare disease, \nEMPAVELI does not qualify for the \nWHO List of Prequalified Medicinal \nProducts20\nAPELLIS SUSTAINABILITY REPORT 2021", "metadata": {"source": "NASDAQ_APLS_2021.pdf", "page": 21, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}